Jacobs Levy Equity Management Inc. Trims Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Jacobs Levy Equity Management Inc. decreased its stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 10.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,123,308 shares of the biopharmaceutical company's stock after selling 136,709 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 1.84% of Sage Therapeutics worth $6,100,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. Picton Mahoney Asset Management boosted its stake in Sage Therapeutics by 126.0% during the fourth quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 3,581 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Sage Therapeutics during the 4th quarter worth about $49,000. Ieq Capital LLC acquired a new stake in shares of Sage Therapeutics in the 4th quarter valued at about $57,000. US Bancorp DE grew its stake in shares of Sage Therapeutics by 22.3% in the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company's stock valued at $67,000 after buying an additional 2,268 shares during the period. Finally, Teacher Retirement System of Texas increased its position in Sage Therapeutics by 21.6% in the 4th quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company's stock valued at $75,000 after buying an additional 2,446 shares in the last quarter. Institutional investors own 99.22% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Scotiabank cut their price target on Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating on the stock in a report on Wednesday, February 12th. Canaccord Genuity Group lowered their target price on Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating on the stock in a research report on Wednesday, February 12th. Wedbush reissued a "neutral" rating and issued a $6.00 price target on shares of Sage Therapeutics in a research report on Wednesday, February 12th. HC Wainwright restated a "neutral" rating and set a $12.00 price target (down previously from $14.00) on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Finally, Bank of America initiated coverage on shares of Sage Therapeutics in a report on Tuesday, March 11th. They set an "underperform" rating and a $5.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, Sage Therapeutics has a consensus rating of "Hold" and an average price target of $8.81.

Sage Therapeutics Stock Up 0.8%

SAGE traded up $0.06 during trading hours on Monday, hitting $6.95. The stock had a trading volume of 152,391 shares, compared to its average volume of 1,213,997. Sage Therapeutics, Inc. has a 1 year low of $4.62 and a 1 year high of $13.47. The company's fifty day simple moving average is $7.42 and its 200 day simple moving average is $6.71. The stock has a market cap of $434.90 million, a PE ratio of -1.05 and a beta of 0.20.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. The business had revenue of $14.06 million for the quarter, compared to the consensus estimate of $14.12 million. During the same quarter in the prior year, the business earned ($1.80) EPS. Sage Therapeutics's revenue for the quarter was up 78.0% compared to the same quarter last year. As a group, equities analysts expect that Sage Therapeutics, Inc. will post -3.52 EPS for the current year.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.